← Back to results
Federal

Finn Sawyer Access to Cancer Testing Act

Source: Congress.gov  ·  1,611 words in original text
This bill requires Medicare, Medicaid and the Children's Health Insurance Program (CHIP) to cover certain cancer genetic tests. The tests covered include microarray analysis, DNA sequencing, RNA sequencing, whole-exome sequencing and other next-generation sequencing (advanced ways to read genetic information) along with explanations of those results. The bill also requires the Secretary of Health and Human Services to run an education program about genomic testing (the study of a person's complete genetic material) for doctors and the public.
People covered by Medicare (health insurance for people 65 and older and some younger people with disabilities), Medicaid (health insurance for low-income people), and CHIP (health insurance for children and pregnant women in low-income families). Doctors and physicians. Clinical laboratories (facilities that perform medical tests). The National Human Genome Research Institute.
• Medicare will pay 80 percent of the cost for cancer diagnostic and laboratory tests, or 100 percent if the doctor accepts assignment (agrees to accept Medicare's payment as full payment) (Sec. 2(a)(2)). • People on Medicare will not have to pay a deductible (an upfront amount patients pay before insurance kicks in) for these cancer tests (Sec. 2(a)(2)). • Cancer diagnostic and laboratory tests can only be done once when cancer is first diagnosed, once if the cancer comes back, and as needed to plan treatment or monitor how the cancer responds to treatment (Sec. 2(a)(1)). • Medicaid must cover cancer diagnostic and laboratory tests for all eligible people starting January 1, 2025 (Sec. 2(b)(1), (2)). • CHIP must cover cancer diagnostic and laboratory tests for children and pregnant women starting January 1, 2025 (Sec. 2(c)). • The Secretary of Health and Human Services and the Director of the National Human Genome Research Institute must create an education program teaching doctors and the public about genomic testing and the role of genetic counselors (doctors who help people understand genetic information) (Sec. 3(a)).
If this bill becomes law, Medicare will start paying for cancer genetic tests six months after the law is signed. Medicaid and CHIP will start covering these tests on January 1, 2025. Patients on these programs will have reduced or no out-of-pocket costs for these tests. Doctors and medical students will receive education about using genetic testing to find cancer mutations (harmful changes in DNA).
Cancer diagnostic and laboratory tests: microarray analysis (a test that checks many genes at once), DNA sequencing (reading the order of genetic material), RNA sequencing (reading genetic instructions that tell cells what to do), whole-exome sequencing (reading the protein-coding parts of all genes), and other next-generation sequencing performed by a clinical laboratory, plus explanation and interpretation of these results, for people diagnosed with cancer.
Medicare coverage begins six months after the law is signed (Sec. 2(a)(1)). Medicaid and CHIP coverage begins January 1, 2025 (Sec. 2(b)(5)(A), (c)).
Important: This plain English summary was generated by AI and is provided for informational purposes only. It is not legal advice. Always consult the official bill text on Congress.gov or a qualified attorney for legal matters.